| Paris | |
| 0 | |
| Biopharmaceutical company discovering and developing drug candidates, for the treatment of neurodegenerative diseases including Alzheimers disease (AD) and orphan tauopathies such as Progressive Supranuclear Palsy | |
| We develop AZP2006 a first-in-class small molecule which modulates protein homeostasis. AZP2006 revolutionary mode of action has been shown to prevent Tau hyperphosphorylation and aggregation in vivo. Its additional neuroprotective properties allow to prevent both cognition and motor deficiencies induced by amyloid and other neurotoxics. AZP2006 will enter clinical phase 2 in 2016. It has obtained an orphan drug status for the treatment of PSP. | |
| VERWAERDE Philippe | |
| www.alzprotect.com | |
| Private Equity |
Fiche créée le 10/04/2016 par 
Guillaume vue 17 fois.